Oligomycin B |
| Catalog No.GC16409 |
mitochondrial F1FO ATP synthase inhibitor
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 11050-94-5
Sample solution is provided at 25 µL, 10mM.
;)
_1-7.$$$37316672@70.jpg');)
;)
;)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
;)
;)
;)
_1124-1138.$$$35908550@30.jpg');)
_766-780.$$$37100057@30.jpg');)
_418-432.$$$36893736@30.jpg');)
_240-255.$$$35108512@29.jpg');)
_533-545.$$$36543525@28.jpg');)
_264-276.$$$36600053@22.jpg');)
_2214998.$$$@0.jpg');)
Oligomycin B is a mitochondrial F1FO ATP synthase inhibitor.
The mitochondrial F1F0 ATP synthase is responsible for the ATP production in mammals via a rotary catalytic mechanism. Studies also show that the F1F0 ATP synthase can switch to an ATP hydrolase, which occurs under conditions during myocardial ischemia.
In vitro: Previous study found that oligomycin B and aurovertin B were able to inhibit both the synthase and the hydrolase function, which not only rendered them difficult to be experimentally used, but also precluded them from being therapeutics. Aurovertin B bound between the subunits catalytic F1 domain of the F1F0 ATPase, where it prevented the conformational changes required for the catalytic cycle of this enzyme, whereas oligomycin bound to the F0 domain and blocked proton flow [1].
In vivo: In a previous animal study, intracranial pressure measurements were performed in SD rats treated by intraperitoneal injection of vehicle, cyclosporine A, or oligomycin B. It was found that cerebral edema and mitochondrial impairment could be significantly worsened by treatment with oligomycin B, whereas a noticeable improvement could be observed in animals that received injections of cyclosporine A [2].
Clinical trial: Up to now, oligomycin B is still in the preclinical development stage.
References:
[1] G. J. Grover and J. Malm. Pharmacological profile of the selective mitochondrial F1F0 ATP hydrolase inhibitor BMS-199264 in myocardial ischemia. Cardiovasc.Ther. 26, 287-296 (2008).
[2] Vlodavsky E, Palzur E, Shehadeh M, Soustiel JF. Post-traumatic cytotoxic edema is directly related to mitochondrial function. J Cereb Blood Flow Metab. 2017 Jan;37(1):166-177.
| Cas No. | 11050-94-5 | SDF | |
| Chemical Name | (1S,2'R,4E,5'R,6R,6'R,7S,8R,10S,11S,12R,14S,15R,16S,18E,20E,22S,25R,28R,29S)-22-ethyl-5',6'-dihydro-7,11,14,15-tetrahydroxy-6'-[(2S)-2-hydroxypropyl]-5',6,8,10,12,14,16,28,29-nonamethyl-spiro[2,26-dioxabicyclo[23.3.1]nonacosa-4,18,20-triene-27,2'-[2H]pyra | ||
| Canonical SMILES | O=C([C@H](C)[C@@H](O)[C@H](C)/C=C/1)[C@@H](C)[C@H](O)[C@@H](C)C([C@](O)(C)[C@H](O)[C@@H](C)C/C=C/C=C/[C@](CC)([H])CC[C@]2([H])[C@H](C)[C@]([C@@H](C)[C@]3(C(C[C@@H](C)[C@](C[C@@H](O)C)([H])O3)=O)O2)([H])OC1=O)=O | ||
| Formula | C45H72O12 | M.Wt | 805.1 |
| Solubility | ≤30mg/ml in ethanol;20mg/ml in DMSO;30mg/ml in dimethyl formamide | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.2421 mL | 6.2104 mL | 12.4208 mL |
| 5 mM | 0.2484 mL | 1.2421 mL | 2.4842 mL |
| 10 mM | 0.1242 mL | 0.621 mL | 1.2421 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >85.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 28 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *